Consensus statement on the management of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Asia

Clinical Respiratory Journal

Volumn 9, Issue 2, 2015, Pages 129-142

  Cao, Bin ^a   Tan, Thuan T ^b   Poon, Edwin ^c   Wang, Jann Tay ^d   Kumar, Suresh ^e   Liam, Chong H Kin ^f   Ahmed, Kamal ^g   Moral, Patrick ^h   Qiu, Haibo ⁱ   Barez, Marie Yvette ^j   Buntaran, Latre ^k   Tampubolon, Oloan E ^l   Thamlikitkul, Visanu ^m  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c Private Practice ^*  (Hong Kong)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e HOSPITAL SUNGAI BULOH   (Malaysia)

^f UNIVERSITY OF MALAYA   (Malaysia)

^g CIVIL HOSPITAL   (Pakistan)

^h UNIVERSITY OF SANTO TOMAS   (Philippines)

ⁱ SOUTHEAST UNIVERSITY   (China)

^j Davao Doctor's Hospital   (Philippines)

^k NATIONAL CARDIOVASCULAR CENTER HARAPAN KITA   (Indonesia)

^l Intensivist   (Indonesia)

^m MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

Antibacterial agents; Asia; Methicillin resistant Staphylococcus aureus; Nosocomial infections; Pneumonia

Indexed keywords

C REACTIVE PROTEIN; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; OXACILLIN; PROCALCITONIN; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASIA; BACTERIAL COLONIZATION; COMMUNITY ACQUIRED PNEUMONIA; DRUG TREATMENT FAILURE; GRAM STAINING; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; STAPHYLOCOCCAL PNEUMONIA; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA; CONSENSUS; CROSS INFECTION; PNEUMONIA, STAPHYLOCOCCAL;

ANTI-BACTERIAL AGENTS; ASIA; CONSENSUS; CROSS INFECTION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, STAPHYLOCOCCAL;

EID: 84926337206     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12134     Document Type: Article

References (79)

1. Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries. Am J Infect Control. 2008;36: S101-108.
2. Anupurba S, Sen MR. Antimicrobial resistance profile of bacterial isolates from Intensive Care Unit: changing trends. J Commun Dis. 2005;37: 58-65.
3. Lo WT, Lin WJ, Chiueh TS, Lee SY, Wang CC, Lu JJ. Changing trends in antimicrobial resistance of major bacterial pathogens, 1985-2005: a study from a medical center in northern Taiwan. J Microbiol Immunol Infect. 2011;44: 131-138.
4. Chung DR, Song JH, Kim SH, etal. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184: 1409-1417.
5. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171: 388-416.
6. Masterton RG, Galloway A, French G, etal. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for antimicrobial chemotherapy. J Antimicrob Chemother. 2008;62: 5-34.
7. Rotstein C, Evans G, Born A, etal. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol. 2008;19: 19-53.
8. Song JH. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Am J Infect Control. 2008;36: S83-92.
9. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10: R97.
10. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26: 166-174.
11. Hanberger H, Walther S, Leone M, etal. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents. 2011;38: 331-335.
12. Chen CB, Chang HC, Huang YC. Nasal meticillin-resistant Staphylococcus aureus carriage among intensive care unit hospitalised adult patients in a Taiwanese medical centre: one time-point prevalence, molecular characteristics and risk factors for carriage. J Hosp Infect. 2010;74: 238-244.
13. Stano P, Avolio M, De Rosa R, etal. An antibiotic care bundle approach based on results of rapid molecular screening for nasal carriage of methicillin-resistant Staphylococcus aureus in the intensive care unit. In Vivo. 2012;26: 469-472.
14. Nair N, Kourbatova E, Poole K, etal. Molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among patients admitted to adult intensive care units: the STAR * ICU trial. Infect Control Hosp Epidemiol. 2011;32: 1057-1063.
15. Choi EY, Huh JW, Lim CM, etal. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med. 2011;37: 639-647.
16. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54: 755-771.
17. Jacob JT, Diazgranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis. 2013;17: e93-100.
18. Ho PL, Lo PY, Chow KH, etal. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect. 2010;60: 140-145.
19. Song JH, Hiramatsu K, Suh JY, etal. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2004;48: 4926-4928.
20. Sun W, Chen H, Liu Y, etal. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob Agents Chemother. 2009;53: 3642-3649.
21. Lin SY, Chen TC, Chen FJ, etal. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. J Microbiol Immunol Infect. 2012;45: 435-441.
22. Chung DR, Baek JY, Kim HA, etal. First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2012;50: 2513-2514.
23. Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Control. 2008;36: S93-100.
24. Song JH, Hsueh PR, Chung DR, etal. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother. 2011;66: 1061-1069.
25. Liu YN, Cao B, Wang H, etal. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35: 739-746.
26. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. J Med Assoc Thai. 2010;93(Suppl. 1): S126-138.
27. Kidwai AA, Razzaq S, Jamal Q, Aatif S, Paracha S. Antibiotic resistance among gram negative bacilli causing ventilator-associated pneumonia. Pak J Chest Med. 2011;17: A3.
28. Shindo Y, Sato S, Maruyama E, etal. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135: 633-640.
29. Seki M, Hashiguchi K, Tanaka A, etal. Characteristics and disease severity of healthcare-associated pneumonia among patients in a hospital in Kitakyushu, Japan. J Infect Chemother. 2011;17: 363-369.
30. Umeki K, Tokimatsu I, Yasuda C, etal. Clinical features of healthcare-associated pneumonia (HCAP) in a Japanese community hospital: comparisons among nursing home-acquired pneumonia (NHAP), HCAP other than NHAP, and community-acquired pneumonia. Respirology. 2011;16: 856-861.
31. Park HK, Song JU, Um SW, etal. Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respir Med. 2010;104: 1729-1735. [Research Support, Non-U.S. Gov't].
32. Jung JY, Park MS, Kim YS, etal. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis. 2011;11: 61.
33. Masterton R, Craven D, Rello J, etal. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. J Antimicrob Chemother. 2007;60: 206-213.
34. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36: 309-332.
35. Fartoukh M, Maitre B, Honore S, Cerf C, Zahar J-R, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med. 2003;168: 173-179.
36. Goodman J, Taylor J, Stevenson K, editors. Impact of gram stain findings on ventilator associated pneumonia therapy. Poster 751. IDWeek; 17-21 October; San Diego, CA, 2012.
37. Cook D, Mandell L. Endotracheal aspiration in the diagnosis of ventilator-associated pneumonia. Chest. 2000;117: 195S-197.
38. Torres A, El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. Chest. 2000;117: 1985-2028.
39. Haque NZ, Zuniga LC, Peyrani P, etal. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest. 2010;138: 1356-1362.
40. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis. 2009;28: 983-987.
41. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44: 1208-1215.
42. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother. 1992;36: 1766-1769.
43. Cruciani M, Gatti G, Lazzarini L, etal. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38: 865-869.
44. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis. 2011;52: 969-974.
45. Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008;14: 116-123.
46. Canut A, Isla A, Betriu C, Gascon AR. Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid vs vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis. 2012;31: 2227-2235.
47. Thamlikitkul V, Tongsai S. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2012;142: 269.
48. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29: 1107-1115.
49. Bosso JA, Nappi J, Rudisill C, etal. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55: 5475-5479.
50. Mimoz O, Rolland D, Adoun M, etal. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32: 775-779.
51. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother. 2004;53: 335-344.
52. Cepeda JA, Whitehouse T, Cooper B, etal. Linezolid vs teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother. 2004;53: 345-355.
53. Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother. 2011;12: 2737-2750.
54. Conte JE, Golden JA, McQuitty M, etal. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother. 2002;46: 2358-2364.
55. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34: 1481-1490.
56. Rubinstein E, Isturiz R, Standiford HC, etal. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47: 1824-1831.
57. Tsuji Y, Hiraki Y, Matsumoto K, etal. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17: 70-75.
58. Wunderink RG, Niederman MS, Kollef MH, etal. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54: 621-629.
59. Peyrani P, Wiemken TL, Zervos M, Kett DH, File TMJ, Stein GE, editors. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) treated with linezolid compared to vancomycin: results from the IMPACT-HAP study. Abstract 1283. IDWeek. 17-21 October; San Diego, CA, 2012.
60. Wiemken TL, Peyrani P, Ford KD, Scerpella EG, Zervos M, Kett DH, editors. Resource utilization in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) treated with linezolid vs vancomycin: results from the IMPACT-HAP study. Poster 1707. IDWeek; 17-21 October; San Diego, CA, 2012.
61. Niederman M, Chastre JE, Solem C, Wan Y, Gao X, Myers DE, editors. Incidence of renal failure and associated economic burden among patients with nosocomial pneumonia caused by methicillin resistant Staphylococcus aureus (MRSA-NP) treated with linezolid or vancomycin: a secondary analysis of a multi-center randomized double-blind clinical trial. Poster 1713. IDWeek; 17-21 October; San Diego, CA, 2012.
62. Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010;15: 507-513.
63. Fagon J, Patrick H, Haas DW, etal. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin vs vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med. 2000;161: 753-762.
64. Jung YJ, Koh Y, Hong SB, etal. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med. 2010;38: 175-180.
65. Drago L, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis. 2007;7: 111.
66. Luna CM, Blanzaco D, Niederman MS, etal. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003;31: 676-682.
67. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med. 2001;163: 1371-1375.
68. Coelho LM, Salluh JI, Soares M, etal. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Critcare. 2012;16: R53.
69. Luyt CE, Combes A, Trouillet JL, Chastre J. Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia. Semin Respir Crit Care Med. 2011;32: 181-187.
70. Sanchez Garcia M, De la Torre MA, Morales G, etal. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303: 2260-2264.
71. Coelho LM, Salluh JI, Soares M, etal. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care. 2012;16: Journal article.
72. Liu C, Bayer A, Cosgrove SE, etal. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52: e18-55.
73. Edgeworth JD. Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care. J Antimicrob Chemother. 2011;66(Suppl. 2): ii41-47.
74. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery T, editors. Randomized evaluation of decolonization vs. universal clearance to eliminate methicillin-resistant Staphylococcus aureus in ICUs (REDUCE MRSA Trial). Abstract 1234. IDWeek; 17-21 October; San Diego, CA, 2012.
75. Fraser TG, Fatica C, Scarpelli M, etal. Decrease in Staphylococcus aureus colonization and hospital-acquired infection in a medical intensive care unit after institution of an active surveillance and decolonization program. Infect Control Hosp Epidemiol. 2010;31: 779-783.
76. Shitrit P, Gottesman BS, Katzir M, Kilman A, Ben-Nissan Y, Chowers M. Active surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreases the incidence of MRSA bacteremia. Infect Control Hosp Epidemiol. 2006;27: 1004-1008.
77. Nizamuddin S, Irfan S, Zafar A. Evaluation of prevalence of low and high level mupirocin resistance in methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital. J Pak Med Assoc. 2011;61: 519-521.
78. Choudhury S, Krishnan PU, Ang B. Prevalence of high-level mupirocin resistance among meticillin-resistant Staphylococcus aureus isolates in a tertiary care hospital in Singapore. J Hosp Infect. 2012;82: 56-57.
79. Matouskova I, Janout V. Current knowledge of methicillin-resistant Staphylococcus aureus and community-associated methicillin-resistant Staphylococcus aureus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152: 191-202.